20 results on '"Varmenot N"'
Search Results
2. Investigation of energy dependance for EBT3 response to irradiation with alpha beams
- Author
-
Basset, A., Koumeir, C., Chiavassa, S., Delpon, G., Le Deroff, C., Frelin, A.-M., Guertin, A., Haddad, F., Métivier, V., Michel, N., Poirier, F., Servagent, N., and Varmenot, N.
- Published
- 2019
- Full Text
- View/download PDF
3. FLASHMOD : vers une plateforme d’irradiation préclinique en protonthérapie FLASH à ARRONAX
- Author
-
Métivier, Vincent, Chiavassa, S., DELPON, G., Guertin, Arnaud, Haddad, Ferid, Koumeir, Charbel, Poirier, Freddy, Ralite, F., Servagent, Noël, Varmenot, N., Laboratoire de physique subatomique et des technologies associées (SUBATECH), Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-IMT Atlantique Bretagne-Pays de la Loire (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Accélérateur pour la Recherche en Radiochimie et Oncologie [Nantes Atlantique] (GIP ARRONAX), Université de Nantes (UN)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], and ANR-11-EQPX-0004,ARRONAXPLUS,Nucléaire pour la Santé(2011)
- Subjects
[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2019
4. Le contrôle de qualité en cours d’irradiation
- Author
-
Dubray, B, Barillot, I, Anah, J, Missohou, F, Varmenot, N, and Batin, E
- Published
- 2003
- Full Text
- View/download PDF
5. Preliminary results of 68Ga-PSMA PET/CT prospective study in prostate cancer occult recurrence patients : diagnostic performance and impact on therapeutic decision-making
- Author
-
Rousseau, C., Le Thiec, M., Ferrer, L., Rusu, D., Rauscher, A., Maucherat, B., Frindel, M., Baumgartner, P., Fleury, V., Denis, A., Varmenot, N., Debeaupuis, E., Campion, L., Kraeber-Bodere, F., Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Service de médecine nucléaire [Saint-Herblain], Centre René Gauducheau-Institut Régional du Cancer Nantes-Atlantique (IRCNA)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Physique médicale [CRG-ICO, Saint-Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Unité de Pharmacie [ICO, Saint Herblain], Délégation à la recherche clinique et à l'innovation [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Unité de Biométrie [ICO, Saint Herblain], Bernardo, Elizabeth, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
- Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,urologic and male genital diseases - Abstract
International audience; Introduction: The aim of this prospective study was to investigate the impact of 68Ga-PSMA-11 PET/CT on current management of prostate cancer patients with occult biochemical recurrence (BCR). Subjects & Methods: 130 hormone-naïve occult BCR (PSA from 0.05 to 1.6 ng/mL) patients were enrolled in a prospective study (NCT03443609). All patients received a radical treatment (prostatectomy +/- radiotherapy) which allowed to an undetectable PSA level. Before PSMA PET/CT, patients were screened by conventional imaging as mpMRI and bone scan (+ trunk SPECT/ CT) and enrolled only if conventional imaging was doubtful or normal. PET images were recorded 1 and 2 hours after injection of 150 MBq of tracer and images interpreted by 2 nuclear physicians. Referring patient physician completed 2 questionnaires to assess PSMA PET imaging influence on therapeutic strategy: one prior and one after PSMA PET/CT indicating treatment plan without and with PSMA PET/CT information respectively. Six months after the end of treatment, a PSA assay was requested to evaluate therapeutic efficacy. Results: Currently, we have complete data analysis of the first 52 patients. After pre-screening, 7 patients were excluded due to positive MRI (5 pts) or bone scan (2 pts). The median time from radical prostatectomy or radiotherapy to BCR was 4.92y (0.6-15.46). Thirty-eight among the 52 patients (73%) had a positive PSMA PET/CT. Ninety-four lesions were detected, 53/94 in lymph nodes (56.4%) predominantly dispatched on pelvic area (75.5%), 25/94 in bone (26.6%) (mostly on axial skeleton) and 12/94 into prostate bed (12.7%). Detection rates were 56 %, 87 % and 74% for patients with PSA value ranging from 0.05 to 0.3, 0.3 to 0.6 and 0.6 to 1.6 ng/ml respectively. Thanks to PSMA PET/CT, therapeutic management changed in 35/52 patients (67.3%). PSMA-positive patients had undetectable PSA level after stereotaxic radiotherapy or focal surgery based on PSMA results in 30.7% (16/52). In this particular hormone naïve patient population, Rauscher’s nomogram (1) was not validate, may be due a too small population. Conclusion: Preliminary results of this prospective study showed, in more than half of patients, a major impact of PSMA PET/CT on treatment management allowing them to benefit very early from focal therapy with the great result for 30% of them of PSA complete response. Reference: (1) Rauscher I., et al: doi:10.1016/j.eururo.2018.01.006
- Published
- 2018
6. Why should we take care about occupational dosimetric impact when routine use of gallium-68 in nuclear medicine ? A preliminary study
- Author
-
Varmenot, N., Ferrer, L., Frindel, M., Rauscher, A., Baumgartner, P., Delaunay, F., Mathey, A., Pitel, C., Zulian, H., Kraeber-Bodere, F., Denis, A., Rousseau, C., Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Unité de physique médicale [ICO, Saint Herblain], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER-UNICANCER, Unité de Pharmacie [ICO, Saint Herblain], Service de médecine nucléaire [Saint-Herblain], Centre René Gauducheau-Institut Régional du Cancer Nantes-Atlantique (IRCNA)-Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Bernardo, Elizabeth, and Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)
- Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer ,[SDV.CAN]Life Sciences [q-bio]/Cancer - Abstract
International audience; Introduction: Medical research in PET/CT diagnosis involving new gallium-68 radiolabelled pharmaceuticals is steadily rising in the last years thanks to the combined improvement of both radionuclide production and radiolabelling. Publications demonstrate benefits for the patient but few studies evaluate the occupational dosimetric impact when use the gallium-68 in routine, in terms of effective and equivalent dose. Subjects & Methods: In this study, extremities, crystallin and whole body exposure are evaluated for three technologists when use of the gallium-68 radiolabelling with DOTATOC peptide (10 runs) requiring handmade steps and PSMA-11 peptide (5 runs) that is an automated process. Electronic dosimeter ED3 (APVL) is used to access to instantaneous dose-rate that can be afterward related to steps of handling. OSL pellets (LANDAUER) are used to measure the cumulative dose. Dosimeters are placed on fingers, protection eyeglass and chest. During the production runs, we separate radiolabelling phase from injection handmade phase to the patient (150 MBq/patient). The annual equivalent and effective doses are extrapolated on a mean of 2.5 patients per day during 52 weeks of 5 days with 68Ga-PSMA-11 or 68Ga-DOTATOC lonely. Results: The measurements show high exposures heterogeneity, confirmed with ED3 measurements that present high punctual peaks during the production runs. For 68Ga-PSMA-11, the median equivalent dose to extremities, per production run and per syringe, is 228 μSv [208; 493] and, at the injection time, the median equivalent dose to extremities per syringe is 212 μSv [188; 278]. For 68Ga-DOTATOC, the median equivalent dose to extremities, per production run and per syringe, is 315 μSv [28; 875] and, at the injection time, the median equivalent dose to extremities per syringe is 493 μSv [111; 1225]. The extrapolated annual equivalent dose to extremities lead to 288 mSv [257; 501] and 525 mSv [90; 1365], respectively for 68Ga-PSMA-11 and 68Ga-DOTATOC. The extrapolated annual equivalent dose to crystallin lead to 6,5 mSv [4,9; 11,7] and 1,3 mSv [background; 113,1], respectively for 68Ga-PSMA-11 and 68Ga-DOTATOC. The extrapolated annual effective dose lead to 1,3 mSv [background; 16,9] and 1,3 mSv [background; 53,3], respectively for 68Ga-PSMA-11 and 68Ga-DOTATOC. Conclusion: This study highlights that the use in routine of radiolabelled gallium-68 could lead to significant equivalent doses for technologist, especially since the protocol is not automated. This advocates strongly for a specific attention when routine use of a new radiopharmaceuticals, particularly on radiation optimisation of radiolabelling protocol and injection phase, also on high practical training of technologist.
- Published
- 2018
7. 57 Study of the camera’s limit of detectability with Iodine-131
- Author
-
Hermouet, R., primary, Ferrer, L., additional, Varmenot, N., additional, Rousseau, C., additional, and Poisson, F., additional
- Published
- 2018
- Full Text
- View/download PDF
8. 42 Deposited dose measurement using bremsstrahlung X-rays
- Author
-
Ralite, F., primary, Koumeir, C., additional, Haddad, F., additional, Metivier, V., additional, Servagent, N., additional, and Varmenot, N., additional
- Published
- 2018
- Full Text
- View/download PDF
9. Beam monitoring and dosimetry tools for radiobiology experiments at the cyclotron ARRONAX
- Author
-
Koumeir, Charbel, Cherel, M., Guertin, Arnaud, Haddad, Ferid, Métivier, Vincent, Michel, Nathalie, Poirier, F., Schwob, L., Servagent, Noël, Varmenot, N., Cyclotron ARRONAX, GIP, Laboratoire SUBATECH Nantes (SUBATECH), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Nantes (UN)-Mines Nantes (Mines Nantes), Nuclear Oncology (CRCINA-ÉQUIPE 13), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), and UNICANCER
- Subjects
[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex] - Abstract
International audience; The ARRONAX (Accélérateur pour la Recherche en Radiochimie et Oncologie à Nantes Atlantique) cyclotron in Saint Herblain - France is a facility delivering alpha particles at 68 MeV (1). One of its purposes is to become a platform for radiobiological studies. The radiobiological studies evolvearound two axes: the low energy range (
- Published
- 2014
10. New beam monitoring tool for radiobiology experiments at the cyclotron ARRONAX
- Author
-
Schwob, L., primary, Koumeir, C., additional, Servagent, N., additional, Cherel, M., additional, Guertin, A., additional, Haddad, F., additional, Métivier, V., additional, Michel, N., additional, Poirier, F., additional, Rahmani, A., additional, and Varmenot, N., additional
- Published
- 2015
- Full Text
- View/download PDF
11. EBT2 films response to alpha radiation at 48.3 MeV
- Author
-
Le Deroff, C., primary, Cherel, M., additional, Guertin, A., additional, Haddad, F., additional, Koumeir, C., additional, Metivier, V., additional, Michel, N., additional, Poirier, F., additional, Servagent, N., additional, Schwob, L., additional, and Varmenot, N., additional
- Published
- 2014
- Full Text
- View/download PDF
12. 108: Beam monitoring and dosimetry tools for radiobiology experiments at the cyclotron ARRONAX
- Author
-
Koumeir, C., primary, Cherel, M., additional, Guertin, A., additional, Haddad, F., additional, Métivier, V., additional, Michel, N., additional, Poirier, F., additional, Schwob, L., additional, Servagent, N., additional, and Varmenot, N., additional
- Published
- 2014
- Full Text
- View/download PDF
13. Radiation safety at ARRONAX
- Author
-
Varmenot, N., primary
- Published
- 2011
- Full Text
- View/download PDF
14. Oxidation Processes of N,S-Diacetyl-<SCP>l</SCP>-cysteine Ethyl Ester: Influence of S-Acetylation
- Author
-
Varmenot, N., Remita, S., Abedinzadeh, Z., Wisniowski, P., Strzelczak, G., and Bobrowski, K.
- Abstract
The mechanism of the •OH-induced oxidation of N,S-diacetyl-
l -cysteine ethyl ester (SNACET) was investigated in aqueous solutions using pulse radiolysis and steady-state γ-radiolysis combined with chromatographic and ESR techniques. The reaction of hydroxyl radicals with SNACET at slightly acidic to neutral pH results in the degradation into acetaldehyde. The underlying mechanism involves a very fast fragmentation of an initially formed hydroxysulfuranyl radical (kfragm ≥ 7.9 × 107 s-1) into acyl radicals (H3 C−CO•) and the respective sulfenic acid (RSOH). Subsequently, these intermediates react via a hydrogen abstraction reaction that yields acetaldehyde and the respective sulfinyl radical (RSO•). In contrast, in very acidic solutions (pH < 2), the •OH-induced oxidation results in the formation of the monomeric sulfur radical cation (SNACET>S•+) which absorbs at λmax = 420 nm. This intermediate is formed with the absolute bimolecular rate constant k = 3.9 × 109 M-1 s-1. It decays in a SNACET concentration independent process (kd = 2.5 × 105 s-1) and in a SNACET concentration dependent process (kS - S = 2.2 × 107 M-1 s-1). The first process involves mainly fragmentation of the carbon−sulfur bond and yields acetylthiyl radical (CH2 &dbd;C(OH)−S•). The latter intermediate was identified via its reaction with oxygen as the thiylperoxyl radical (RSOO•), characterized by a transient absorption band with λmax = 540 nm. The second process represents the association of the monomeric sulfur radical cation (SNACET>S•+) with a second nonoxidized SNACET molecule to form intermolecularly three-electron-bonded (>S∴S<)+ dimeric radical cation. The low rate constant (kS - S ) is in line with the high stability of the monomeric sulfur radical cation (SNACET>S•+) because of spin delocalization in the carbonyl group. The monomeric radical cation (SNACET>S•+) is alternatively produced in slightly acidic solutions using the sulfate radical anion, SO4 •-, as an one-electron oxidant. This paper provides further evidence that the nature of the neighboring group affects the ultimate course of the sulfide oxidation.- Published
- 2001
15. Effective Management of 177Lu-DOTA0-Tyr3-Octreotate Extravasation.
- Author
-
Maucherat B, Varmenot N, Fleury V, Senellart H, and Rousseau C
- Subjects
- Humans, Male, Octreotide adverse effects, Octreotide metabolism, Radionuclide Imaging, Coordination Complexes adverse effects, Coordination Complexes metabolism, Octreotide analogs & derivatives
- Abstract
Abstract: Radiopharmaceutical extravasation is a known nuclear medicine adverse effect, mostly with no complication in case of diagnostic radiopharmaceutical. However, a therapeutic radiopharmaceutical extravasation may have clinical consequences and must be treated quickly and effectively. We report here a case of 177Lu-DOTA0-Tyr3-octreotate extravasation., Competing Interests: Conflicts of interest and sources of funding: none declared., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
16. Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.
- Author
-
Rousseau C, Le Thiec M, Ferrer L, Rusu D, Rauscher A, Maucherat B, Frindel M, Baumgartner P, Fleury V, Denis A, Morel A, Varmenot N, Debeaupuis E, Campion L, and Kraeber-Bodéré F
- Subjects
- Aged, Decision Making, Gallium Isotopes, Gallium Radioisotopes, Humans, Kallikreins blood, Male, Middle Aged, Neoplasm Recurrence, Local blood, Positron Emission Tomography Computed Tomography methods, Prospective Studies, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Membrane Glycoproteins, Neoplasm Recurrence, Local diagnostic imaging, Neoplasm Recurrence, Local therapy, Organometallic Compounds, Prostatic Neoplasms diagnostic imaging, Prostatic Neoplasms therapy, Radiopharmaceuticals
- Abstract
Background: In this prospective study (NCT03443609), we investigated the impact of 68Ga-PSMA-11 PET-CT on the treatment plan and therapeutic response obtained for patients with prostate cancer (PCa) presenting a recurrence with a low rising PSA., Methods: One hundred thirty hormone-naive (PSA < 1.5 ng/mL) patients were enrolled. All patients received radical treatment. PET images were recorded 1 and 2 hours after injection of tracer and interpreted by two independent nuclear physicians. Six months after treatment ended, a PSA assay was requested to evaluate the therapeutic efficacy of the treatment based on PSMA results., Results: Data analysis for the first 52 included patients has been completed. 68Ga-PSMA-11-positive lesions were detected in 38/52 (73.1%) patients. Ninety-four lesions were detected as follows, 53/94 in lymph nodes (56.4%), 25/94 in bone (26.6%), and 12/94 into the prostate bed (12.7%). Detection rates were 58%, 81%, and 82% for serum PSA levels lower than 0.25 ng/mL, between 0.25 to ≤ 0.69 ng/mL and 0.70 ng/mL, respectively. As a result of the PSMA PET-CT, therapeutic management changed in 38/52 patients (73.1%). Patients had undetectable serum PSA levels after treatment guided by 68Ga-PSMA-11 PET-CT results in 10/52 (19.2%) cases and with a PSA decrease of over 60% in 18/52 (34.6%) patients., Conclusion: Whilst our patient population presented a very low PSA level, preliminary results of the 68Ga-PSMA PET-CT study showed recurrence localization in more than half of the patients and this had a major clinical impact, as it resulted in treatment change in more than half of the patients and a significant decrease in PSA levels in a third of patients., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
17. THE RADIOBIOLOGICAL PLATFORM AT ARRONAX.
- Author
-
Koumeir C, De Nadal V, Cherubini R, Cherel M, Garrido E, Gouard S, Guertin A, Haddad F, Métivier V, Michel N, Poirier F, Servagent N, Sounalet T, and Varmenot N
- Subjects
- Equipment Design, France, Humans, Cyclotrons, Radiobiology instrumentation
- Abstract
The cyclotron ARRONAX can deliver different types of particles (protons, deuterons, alpha-particles) in an energy range up to 68 MeV. One of its six experimental halls is dedicated to studying the interactions of radiation with matter including living matter. A horizontal beamline for cell irradiation has been setup and characterized. The radiobiological characterization was done in terms of V79 cells survival after irradiation with 68 MeV protons. The results demonstrate that radiobiological studies can be successfully performed confirming the high potential of the facility., (© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
18. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
- Author
-
Huclier-Markai S, Alliot C, Varmenot N, Cutler CS, and Barbet J
- Subjects
- Antibodies chemistry, Antibodies immunology, Chelating Agents chemistry, Clinical Trials as Topic, Half-Life, Humans, Molecular Targeted Therapy, Neoplasms diagnosis, Neoplasms immunology, Radioisotopes isolation & purification, Radiometry, Radiopharmaceuticals isolation & purification, Alpha Particles therapeutic use, Neoplasms radiotherapy, Radioimmunotherapy, Radioisotopes therapeutic use, Radiopharmaceuticals therapeutic use
- Abstract
Alpha-particles are of considerable growing interest for Targeted Alpha Therapy (TAT). TAT gains more attention as new targets, chemical labeling techniques and α-particle emitters are developed but translation of TAT into the clinic has been slow, in part because of the limited availability and the short physical half-lives of some of the available α-particle emitters. This article is an up-to-date overview of the literature concerning α-emitters used for TAT of cancer. It briefly describes the nuclear characteristics, the production parameters (targets, extraction and purification), the complexation properties of these radionuclides to chelates and biological vectors and finally draws-upon the preclinical and clinical studies that have been performed over the past two decades. Radiobiology and dosimetry aspects are also presented in this paper.
- Published
- 2012
- Full Text
- View/download PDF
19. Energies, stability and structure properties of radicals derived from organic sulfides containing an acetyl group after the *OH attack: ab initio and DFT calculations vs experiment.
- Author
-
Bergès J, Varmenot N, Scemama A, Abedinzadeh Z, and Bobrowski K
- Abstract
The mutual location of the sulfur atom and the acetyl group was found to affect significantly the (*)OH-induced oxidation mechanism of the organic sulfides containing either an alpha- or beta-positioned acetyl group. This phenomenon was reflected in formation of different intermediate products observed in pulse radiolysis experiments (Varmenot et al. J. Phys. Chem. A. 2004, 108, 6331-6346). In order to obtain a better support for the earlier interpretation of the experimental data, quantum mechanical calculations were performed using a density functional theory method (DFT-B3LYP) and the ab initio method (Møller-Plesset perturbation theory MP2) for optimizations and energy calculations of the parent molecules and radicals and radical cations derived from them. In accordance with experiments, it was found that the alpha-positioned acetyl group in S-ethylthioacetate (SETAc) destabilizes hydroxysulfuranyl radicals and monomeric sulfur radical cations. Instead, formation of stable C-centered radicals of the alpha-(alkylthio)alkyl-type was found energetically favorable, the H3C-(*)CH-S-C(=O)CH3 radical, in particular. On the other hand, the beta-positioned acetyl group in S-ethylthioacetone (SETA) does not destabilize hydroxysulfuranyl radicals, monomeric sulfur radical cations, and dimeric sulfur radical cations. Moreover, the alpha-(alkylthio)alkyl radicals of the type -S-(*)CH-C(=O)- were found to be particularly stabilized. The calculated transition states pointed toward the efficient direct conversion of the hydroxysulfuranyl radicals derived from SETAC and SETA radicals into the respective C-centered radicals. This reaction pathway, important in neutral solutions, is responsible for the absence of the dimeric radical cations of SETAc at low and high concentrations and of the dimeric radical cations of SETA at relatively low concentrations of the solute.
- Published
- 2008
- Full Text
- View/download PDF
20. Evaluation of a rigid registration method of lung perfusion SPECT and thoracic CT.
- Author
-
Gutman F, Hangard G, Gardin I, Varmenot N, Pattyn J, Clement JF, Dubray B, and Véra P
- Subjects
- Aged, Analysis of Variance, Contrast Media, Female, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Posture, Radiography, Thoracic instrumentation, Reproducibility of Results, Lung Neoplasms diagnostic imaging, Phantoms, Imaging, Tomography, Emission-Computed, Single-Photon instrumentation, Tomography, X-Ray Computed instrumentation
- Abstract
Objective: The objective of our study was to evaluate a rigid registration method in lung perfusion SPECT using thoracic CT as a standard., Materials and Methods: The reproducibility of markers selection and the robustness of the method were assessed on a torso phantom. The accuracy of registration regarding the number and location of markers and the breathing state during CT was evaluated on eight patients using 10 external markers placed around the thorax before SPECT and CT acquisitions. The accuracy of registration was assessed using the mean errors (ME) between 10 markers after registration., Results: Registration using external markers on a phantom was accurate (ME, < 3 mm) when rotation was less than 40 degrees (p = 0.02). The accuracy of registration improved markedly from four to six markers for phantom (5.5-3.6 mm) and patients (11.2-9.5 mm) and then remained constant up to 10 markers. The ME was less when using markers that well encompassed the thorax for phantom and patients (p = 0.02 and p = 0.05, respectively). The use of four anatomic markers was not accurate (ME, 20 mm)., Conclusion: The registration method is reproducible and accurate, and six external markers were required to get an ME of less than 10 mm in patients.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.